At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Apr 14, 2026 at 07:00 ET
Ligand Pharmaceuticals announced FDA approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS), a rare kidney disorder, marking the first approved therapy for this condition. Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI, which expands its commercial potential beyond IgA nephropathy and positions it as a key driver of future royalty growth.
- FDA approved FILSPARI for FSGS in patients aged 8+ without nephrotic syndrome, the first and only approved treatment for this indication.
- Ligand receives a 9% royalty on worldwide net sales of FILSPARI, which is already the most prescribed FDA-approved drug for IgA nephropathy.
- Phase 3 DUPLEX study showed a 46% reduction in proteinuria overall and 48% in non-nephrotic syndrome patients, with statistically significant results.
- Addressable U.S. population estimated at over 30,000 patients with FSGS without nephrotic syndrome.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access